Abbott Laboratories $ABT Shares Bought by Arete Wealth Advisors LLC

by · The Cerbat Gem

Arete Wealth Advisors LLC lifted its position in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 1.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 22,802 shares of the healthcare product maker’s stock after purchasing an additional 352 shares during the period. Arete Wealth Advisors LLC’s holdings in Abbott Laboratories were worth $3,025,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in ABT. Great Lakes Advisors LLC grew its stake in Abbott Laboratories by 9.1% during the 1st quarter. Great Lakes Advisors LLC now owns 1,233,576 shares of the healthcare product maker’s stock worth $163,515,000 after buying an additional 103,166 shares during the last quarter. Voleon Capital Management LP boosted its holdings in shares of Abbott Laboratories by 243.4% in the first quarter. Voleon Capital Management LP now owns 8,297 shares of the healthcare product maker’s stock valued at $1,101,000 after acquiring an additional 5,881 shares during the period. Fred Alger Management LLC grew its position in shares of Abbott Laboratories by 353.6% during the first quarter. Fred Alger Management LLC now owns 139,431 shares of the healthcare product maker’s stock worth $18,496,000 after acquiring an additional 108,690 shares during the last quarter. CTC Alternative Strategies Ltd. acquired a new position in shares of Abbott Laboratories in the 1st quarter valued at $576,000. Finally, Ashton Thomas Private Wealth LLC raised its position in Abbott Laboratories by 4.5% in the 1st quarter. Ashton Thomas Private Wealth LLC now owns 47,884 shares of the healthcare product maker’s stock valued at $6,352,000 after purchasing an additional 2,081 shares during the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Price Performance

Shares of NYSE:ABT opened at $132.92 on Monday. Abbott Laboratories has a 52 week low of $110.86 and a 52 week high of $141.23. The company has a 50-day moving average price of $130.68 and a 200 day moving average price of $131.38. The company has a market cap of $231.33 billion, a P/E ratio of 16.66, a PEG ratio of 2.52 and a beta of 0.69. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT – Get Free Report) last released its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.26. The company had revenue of $11.14 billion for the quarter, compared to analysts’ expectations of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The firm’s quarterly revenue was up 7.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th were given a $0.59 dividend. The ex-dividend date was Tuesday, July 15th. This represents a $2.36 annualized dividend and a yield of 1.8%. Abbott Laboratories’s dividend payout ratio is presently 29.57%.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Leerink Partnrs raised shares of Abbott Laboratories to a “hold” rating in a research report on Monday, June 16th. Leerink Partners started coverage on Abbott Laboratories in a report on Monday, June 16th. They set a “market perform” rating and a $143.00 price target on the stock. Royal Bank Of Canada boosted their price target on Abbott Laboratories from $145.00 to $147.00 and gave the company an “outperform” rating in a research report on Tuesday, July 15th. William Blair raised Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, July 17th. Finally, Wells Fargo & Company lowered their target price on Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating on the stock in a research note on Friday, July 18th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus target price of $144.47.

View Our Latest Stock Analysis on Abbott Laboratories

Insider Buying and Selling

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the business’s stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the sale, the chief financial officer directly owned 51,003 shares in the company, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Company Profile

(Free Report)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Further Reading

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).